Study of 18F-MFBG PET Imaging to Detect and Assess Neuroblastoma in Children and Adolescents

What this Trial Is About

This research aims to evaluate the use of 18F-metafluorobenzylguanidine 18F-MFBG positron emission tomography PET in diagnosing neuroblastoma, a cancer that often expresses norepinephrine transporter NET. The current imaging methods using radioactive iodine-labeled compounds have limitations such as low resolution, long procedures, and difficulty detecting small lesions. This study will look at the safety, image quality, and diagnostic ability of 18F-MFBG, which can be used shortly after injection and shows promise based on preliminary data. Participants will receive a single intravenous dose of 18F-MFBG at 2-5 MBqkg. After 60 minutes, patients will undergo a PETCT or PETMR scan to visualize the tumor. This approach allows for quicker imaging compared to prior methods and aims to better detect neuroblastoma lesions. The study will compare this imaging techniques performance with other images and assess its value for predicting progression-free survival in high-risk patients. During the study, patients will be monitored for diagnostic efficacy over an average of 1.5 years, with secondary outcomes tracked for up to 3-4 years in some cases. Assessments include image quality, tumor burden evaluation, and safety observations. Participants will be involved in the injection and scanning procedures, with follow-up to assess prognosis and imaging performance. The total participation duration varies depending on outcome tracking needs.

18F-mFBG PET Imaging in the Evaluation of Neuroblastoma